A polymer, preparation method and application thereof
By developing a polymer that forms a higher-level assembly under the action of alkaline phosphatase in the tumor microenvironment, the problem of tumor cell killing and metastasis inhibition is solved, and efficient killing and metastasis inhibition is achieved on the tumor, reducing the Cell resistance.
Patent Information
- Application Number
- CN202210747757.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-06-29
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-06-29
AI Technical Summary
The prior art is difficult to effectively achieve tumor cell killing and metastasis inhibition in the tumor microenvironment, and traditional chemotherapy has cell resistance problems.
Develop a polymer that removes phosphate under the action of alkaline phosphatase, restores the β-sheet structure to form a higher-level assembly that can form in cells or tumor stromas and induces tumor cells to apoptosis Death and inhibit tumor growth and metastasis.
This polymer forms a higher-level assembly under alkaline phosphatase catalytic conditions, significantly killing tumor cells with high expression of alkaline phosphatase, inhibiting tumor growth and metastasis, and reducing cell drug resistance.
Smart Images

Figure BDA0003719954510000021 
Figure BDA0003719954510000025 
Figure BDA0003719954510000041
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of polymer materials, in particular to a polymer, a preparation method and application thereof. Background Art
[0002] In nature, insoluble assemblies can affect the state and movement ability of living organisms. For example, the toxicity of assemblies to nerve cells can cause Alzheimer's disease, and human defensin-6 can combine with bacteria to form a network structure to limit bacterial invasion. Inspired by these processes, researchers have conducted a series of explorations in the field of triggering the formation of assemblies for disease treatment in pathological environments. Among them, enzyme-catalyzed peptide self-assembly is an emerging field of tumor treatment. Enzyme-catalyzed self-assembly is the chemical structure transformation of peptides under the catalysis of enzymes, and then the formation of assemblies driven by hydrogen bonds or hydrophilic and hydrophobic interactions. These formed assemblies can be formed inside or outside cells, interfering with the normal life activities of cells to induce cell death or forming physical barriers to inhibit tumor metastasis. Compared with traditional chemotherapy, enzyme-catalyzed self-assembly treatment has many advantages, such as reducing cell resistance by directly blocking and killing cells outside or forming assemblies inside cells to inhibit drug efflux. Compared with ordinary nanomedicines, this material can accumulate specifically at the tumor site for a longer time by deforming at the tumor site.
[0003] For tumor treatment, it is crucial to simultaneously achieve efficient tumor cell killing and construct an effective physical barrier to inhibit tumor metastasis. It is a challenging task to use a living self-assembly strategy to simultaneously achieve cell killing and metastasis inhibition. Therefore, it is very necessary to develop a system with an enzyme-catalyzed morphological transformation based on the tumor microenvironment. Summary of the invention
[0004] In view of this, the technical problem to be solved by the present invention is to provide a polymer, wherein the polymer of the present invention removes phosphate under the action of alkaline phosphatase, and the chain segments restore the β-folded structure to form a higher-level assembly. The assembly can inhibit tumor growth and tumor metastasis.
[0005] The present invention provides a polymer represented by formula (I),
[0006]
[0007] Where, R1= —CH2—, R2=CH3、H、 X=10~1000; m=1~100; n=1~100.
[0008] Preferably, X=10-90; m=15-40; n=2-8.
[0009] The present invention provides a method for preparing a polymer represented by formula (I), comprising:
[0010] The initiator is dissolved in a solvent to initiate a polymerization reaction between the monomer of the structure of formula (II) and the monomer of the structure of formula (III), to obtain the product; the initiator is amino-terminated polyethylene glycol monomethyl ether;
[0011]
[0012] Where, R1= —CH2—, R2=CH3、H、
[0013] Preferably, the solvent is anhydrous N,N-dimethylformamide; the initiator is anhydrous amino-terminated polyethylene glycol monomethyl ether; and the molecular weight of the initiator is 500 to 50,000.
[0014] Preferably, the molar ratio of the monomer of formula (II) to the monomer of formula (III) is (1-100): (1-100);
[0015] The molar ratio of the monomer of the initiator formula (II) to the monomer of the initiator formula (III) is 1:(1-100):(1-100).
[0016] Preferably, the polymerization reaction is carried out under the protection of an inert gas; the inert gas includes nitrogen; the polymerization reaction temperature is 20 to 30° C., and the time is 2 to 3 days.
[0017] Preferably, the reaction further comprises sedimentation and drying to obtain a reactant; the reactant is dissolved in a solvent, trimethylsilyl bromide and triethylamine are added for reflux reaction, the solvent is removed, the pH value is adjusted after the solid is dissolved, and freeze-dried to obtain the product.
[0018] Preferably, the precipitation is precipitation in icy ether; the drying is vacuum drying; the solvent is chloroform; the temperature of the reflux reaction is 55-65° C., and the time is 7-10 hours.
[0019] The present invention provides use of any of the above-mentioned polymers or a polymer prepared by any of the above-mentioned preparation methods in preparing drugs for treating tumors.
[0020] The present invention provides an assembly, which is obtained by reacting a polymer described in any one of the above technical solutions or a polymer prepared by the preparation method described in any one of the above technical solutions with alkaline phosphatase and then self-assembling.
[0021] Compared with the prior art, the present invention provides a polymer represented by formula (I). The polymer of the present invention can undergo a morphological transformation under the catalytic conditions of alkaline phosphatase: under the action of alkaline phosphatase, the phosphate group is removed, and the chain segments restore the β-folded structure, thereby forming a higher-level assembly. The assembly can be formed on cells, cell membranes or tumor matrix, induce tumor cell apoptosis, and inhibit tumor growth and metastasis. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 The hydrogen nuclear magnetic resonance spectrum of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention;
[0023] Figure 2 Ultra-low temperature scanning electron microscopy images of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention before and after ALP catalysis;
[0024] Figure 3 Cell survival rate after different cells are treated with polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention;
[0025] Figure 4 This is a biological electron microscopic image of cells treated with polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention;
[0026] Figure 5 This is a graph showing the relationship between polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention and tumor size;
[0027] Figure 6 This is an H&E staining image of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared by the present invention and tumor liver sections. DETAILED DESCRIPTION
[0028] The present invention provides a polymer, a preparation method and application thereof. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve the same. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and they all fall within the scope of protection of the present invention. The method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0029] The present invention provides a polymer represented by formula (I),
[0030]
[0031] Where, R1= —CH2—, R2=CH3、H、
[0032] X=10-1000; preferably 10-90; more preferably 20-60; most preferably 45.
[0033] m=1-100; preferably 15-40; more preferably 20-35; most preferably 25.
[0034] n=1-100; preferably 2-8; more preferably 3-6; most preferably 4.
[0035] The material of the present invention mainly includes polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine), polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-valine), polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-leucine), polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-alanine), polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-valine), polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-leucine), polyethylene glycol monomethyl ether-b-poly(threonine phosphate-co-alanine), polyethylene glycol monomethyl ether-b-poly(threonine phosphate-co-valine), polyethylene glycol monomethyl ether-b-poly(threonine phosphate-co-leucine).
[0036] The present invention provides a polymer represented by formula (I). The polymer of the present invention can undergo a morphological transformation under the catalytic conditions of alkaline phosphatase: under the action of alkaline phosphatase, the phosphate group is removed, and the chain segments restore the β-folded structure, thereby forming a higher-level assembly. The assembly can be formed on cells, cell membranes, or tumor matrix, inducing tumor cell apoptosis and inhibiting tumor growth and metastasis.
[0037] The present invention provides a method for preparing a polymer represented by formula (I), comprising:
[0038] The initiator is dissolved in a solvent to initiate a polymerization reaction between the monomer of the structure of formula (II) and the monomer of the structure of formula (III), to obtain the product; the initiator is amino-terminated polyethylene glycol monomethyl ether;
[0039]
[0040] Where R1 = —CH2—, R2=CH3、H、
[0041] The method for preparing the polymer represented by formula (I) provided by the present invention firstly dissolves the initiator in a solvent. The solvent is preferably anhydrous N,N-dimethylformamide;
[0042] The initiator of the present invention is anhydrous amino-terminated polyethylene glycol monomethyl ether. The molecular weight (Mw) of the initiator is preferably 500 to 50,000; preferably 1,000 to 10,000; and most preferably 2,000.
[0043] The specific preparation method of the anhydrous amino-terminated polyethylene glycol monomethyl ether of the present invention is preferably:
[0044] a) dissolving amino-terminated polyethylene glycol monomethyl ether in a first organic solvent, stirring and separating water to remove excess water, to obtain a first reaction solution.
[0045] The first organic solvent of the present invention is toluene, the reaction temperature is 120-135° C., the stirring time is 3-6 hours, and a water separator is used for water separation operation.
[0046] You can also azeotropize in an oil bath to remove excess water.
[0047] b) removing the solvent in the first reaction solution by vacuum distillation to obtain a first reaction solid, that is, removing toluene by vacuum distillation.
[0048] The initiator is dissolved in a solvent to initiate the polymerization reaction of the monomers of the structure of formula (II) and the monomers of the structure of formula (III).
[0049] The molar ratio of the monomer of formula (III) to the monomer of formula (II) of the present invention is preferably (1-100): (1-100); more preferably (15-40): (2-8);
[0050] The molar ratio of the initiator, the monomer of formula (III) and the monomer of formula (II) is 1:(1-100):(1-100); more preferably 1:(15-40):(2-8); most preferably 1:25:4.
[0051] The polymerization reaction of the present invention is carried out under the protection of an inert gas; the inert gas preferably includes nitrogen; it can also be helium, neon, argon, etc.
[0052] The polymerization reaction temperature of the present invention is 20-30° C. and the reaction time is 2-3 days.
[0053] The reaction of the present invention further comprises sedimentation and drying to obtain a reactant;
[0054] The precipitation is precipitation in ice ether; the drying is vacuum drying or dialysis freeze drying;
[0055] The reactant is dissolved in a solvent, trimethylsilyl bromide and triethylamine are added for reflux reaction, the solvent is removed, the pH value is adjusted after the solid is dissolved, and the solid is freeze-dried to obtain the product; the solvent is chloroform;
[0056] The temperature of the reflux reaction of the present invention is 55-65° C. and the time is 7-10 hours.
[0057] The solvent removal is preferably performed by vacuum removal of the solvent;
[0058] The remaining solid after removing the solvent is dissolved in deionized water with EDTA added, and then the pH of the solution is adjusted to near neutral, dialyzed and freeze-dried to obtain the product.
[0059] The present invention provides use of any of the above-mentioned polymers or a polymer prepared by any of the above-mentioned preparation methods in preparing drugs for treating tumors.
[0060] The treatment described in the present invention includes inducing tumor cell apoptosis and inhibiting tumor growth and metastasis.
[0061] The experiment of the present invention proves that the polymer of the present invention has a significant killing effect on tumor cells with high expression of alkaline phosphatase.
[0062] The experiments of the present invention prove that the polymer of the present invention can undergo morphological changes in cells and can induce cell apoptosis.
[0063] The experiments of the present invention prove that the polymer of the present invention has an inhibitory effect on tumor growth.
[0064] The experiments of the present invention prove that the polymer of the present invention has the effect of inhibiting tumor metastasis.
[0065] The present invention provides an assembly, which is obtained by reacting a polymer described in any one of the above technical solutions or a polymer prepared by the preparation method described in any one of the above technical solutions with alkaline phosphatase and then self-assembling.
[0066] That is, the polymer of formula (I) of the present invention undergoes the following reaction under the catalysis of alkaline phosphatase:
[0067]
[0068] Where R1 = —CH2—, R2=CH3、H、
[0069] Alkaline phosphatase is widely distributed inside and outside cells. Alkaline phosphatase catalyzes the removal of phosphate to restore the β-folded structure to form an assembly. The present invention uses polyamino acids such as polyalanine, polyleucine, polyvaline, etc. that can form a β-folded structure as a skeleton, and copolymerizes with phosphorylated tyrosine, phosphorylated threonine, and serine to achieve similar functions in vivo. The presence of phosphate destroys the β-folded structure of the polypeptide segment. Under the action of alkaline phosphatase, the phosphate is removed, and the chain segment restores the β-folded structure, thereby forming a higher-level assembly. The assembly can be formed on cells, cell membranes, or tumor stroma to inhibit tumor growth and metastasis.
[0070] In order to further illustrate the present invention, a polymer provided by the present invention, its preparation method and application are described in detail below in conjunction with embodiments.
[0071] Example 1: Preparation of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine)
[0072] The preparation of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) is as follows: 1 mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) is dissolved in 100 mL of toluene, azeotroped in an oil bath at 130°C for 4 hours to remove excess water, and then toluene is removed by reduced pressure distillation. Anhydrous amino-terminated polyethylene glycol monomethyl ether is dissolved in 20 mL of anhydrous N,N-dimethylformamide, and then 25 mmol of alanine-ring anhydride and 4 mmol of diethoxyphosphoryltyrosine-N-ring anhydride are added under nitrogen protection and stirred at 25°C for 72 hours. The reaction solution is precipitated in 10 times of ice ether, and the ether on the surface of the material is drained by a vacuum drying pump. The drained product is dissolved in chloroform, trimethylsilyl bromide and triethylamine are added, and heated to reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine).
[0073] Figure 1 It is the nuclear magnetic resonance hydrogen spectrum of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) and polyethylene glycol monomethyl ether-b-poly(diethoxyphosphoryltyrosine-co-alanine).
[0074] Example 2: Preparation of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-valine)
[0075] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically remove excess water in an oil bath at 130°C for 4 hours, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of valine-intracyclic anhydride and 4mmol of diethoxyphosphoryltyrosine-intracyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutral, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-valine)
[0076] Example 3: Preparation of polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-leucine)
[0077] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically in an oil bath at 130°C for 4 hours to remove excess water, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of leucine-intracyclic anhydride and 4mmol of diethoxyphosphoryltyrosine-intracyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-leucine).
[0078] Example 4: Preparation of polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-alanine)
[0079] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically remove excess water in an oil bath at 130°C for 4 hours, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of alanine-cyclic anhydride and 4mmol of diethoxyphosphorylserine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-alanine).
[0080] Example 5: Preparation of polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-valine)
[0081] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically remove excess water in an oil bath at 130°C for 4 hours, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of valine-cyclic anhydride and 4mmol of diethoxyphosphorylserine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-valine).
[0082] Example 6: Preparation of polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-leucine)
[0083] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically in an oil bath at 130°C for 4 hours to remove excess water, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of leucine-cyclic anhydride and 4mmol of diethoxyphosphorylserine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-leucine).
[0084] Example 7: Preparation of polyethylene glycol monomethyl ether-b-poly(threonine phosphate-co-alanine)
[0085] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically in an oil bath at 130°C for 4 hours to remove excess water, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of alanine-cyclic anhydride and 4mmol of diethoxyphosphorylthreonine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-alanine).
[0086] Example 8: Preparation of polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-valine)
[0087] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically remove excess water in an oil bath at 130°C for 4 hours, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of valine-cyclic anhydride and 4mmol of diethoxyphosphorylthreonine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-valine).
[0088] Example 9: Preparation of polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-leucine)
[0089] Dissolve 1mmol of amino-terminated polyethylene glycol monomethyl ether (Mw=2000) in 100mL of toluene, azeotropically remove excess water in an oil bath at 130°C for 4 hours, and then remove toluene by vacuum distillation. Dissolve anhydrous amino-terminated polyethylene glycol monomethyl ether in 20mL of anhydrous N,N-dimethylformamide, then add 25mmol of valine-cyclic anhydride and 4mmol of diethoxyphosphorylthreonine-cyclic anhydride under nitrogen protection and stir at 25°C for 72 hours. Sediment the reaction solution in 10 times of ice ether, and drain the ether on the surface of the material by a vacuum drying pump. Dissolve the dried product in chloroform, add trimethylsilyl bromide and triethylamine, and heat under reflux at 60 degrees for 8 hours. Subsequently, the solvent was removed by vacuum, and the remaining solid was dissolved with deionized water to which EDTA was added, and then the pH of the solution was adjusted to near neutrality, dialyzed and freeze-dried to obtain polyethylene glycol monomethyl ether-b-poly(serine phosphate-co-leucine).
[0090] Example 10: Morphological characterization of the material prepared in Example 1
[0091] The polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared in Example 1 was prepared into nanoparticles, and then alkaline phosphatase was added and reacted at 37°C for 24 hours. The materials before and after the reaction were photographed with an ultra-low temperature scanning electron microscope, as shown in FIG. Figure 2 As shown, the nanoparticles are transformed into a three-dimensional network structure.
[0092] Example 11: Evaluation of the killing effect of the material on tumor cells with high expression of alkaline phosphatase
[0093] The polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared in Example 1 was prepared into nanoparticles, and then incubated with 4T1 cells and 293T cells at different concentration gradients. After 48 hours, the cell viability was detected by CCK-8 method. Figure 3 As shown, compared with 293T cells, the material showed a significant killing effect on 4T1 cells, indicating that the material prepared in Example 2 has a significant killing effect on tumor cells with high expression of alkaline phosphatase.
[0094] Example 12: Evaluation of intracellular assembly of the material prepared in Example 1
[0095] The polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) prepared in Example 1 was prepared into nanoparticles, and then 0.5 mg / mL was co-incubated with 4T1 cells for 24 h, and then trypsinized, the cells were collected, and the presence of assemblies in the cells was observed by biological electron microscopy. Figure 4 As shown, there are obvious filamentous structures in the cells, and the presence of apoptotic bodies indicates that the cells are in an apoptotic state. This shows that the material can undergo morphological changes in cells and can induce cell apoptosis.
[0096] Example 13: Evaluation of the tumor treatment effect of the material prepared in Example 1 that undergoes morphological transformation catalyzed by alkaline phosphatase.
[0097] Tumor-bearing mice were injected with saline, polyethylene glycol monomethyl ether-b-poly(tyrosine-co-alanine) (EG 45 -Y4A 25 ) (25 mg / kg mouse body weight), the materials prepared in Example 1, polyethylene glycol monomethyl ether-b-poly(tyrosine phosphate-co-alanine) (EG 45 -pY4A 25 )(25 mg / kg mouse body weight, 50 mg / kg mouse body weight), injected once every two days, and the changes in tumor volume of mice were monitored. Figure 5 As shown, the tumor growth of the material prepared in Example 1 was significantly slower, proving that the prepared material had a certain inhibitory effect on tumor growth. Tumor metastasis was evaluated by H&E staining of liver sections, such as Figure 6 As shown, the material group EG prepared in Example 1 45 -pY4A 25 Tumor metastasis was significantly less than that in the saline group and EG group 45 -Y4A 25 group, indicating that the material prepared in Example 1 has a certain effect in inhibiting tumor metastasis.
[0098] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A polymer represented by formula (I), Wherein X=10~90; m=2~8; n=15~40.
2. A method for preparing a polymer represented by formula (I) according to claim 1, characterized in that: include: The initiator is dissolved in a solvent to initiate a polymerization reaction between the monomer of the structure of formula (II) and the monomer of the structure of formula (III), to obtain the product; the initiator is amino-terminated polyethylene glycol monomethyl ether; 3. The preparation method according to claim 2, characterized in that: The solvent is anhydrous N,N-dimethylformamide; the initiator is anhydrous amino-terminated polyethylene glycol monomethyl ether; and the molecular weight of the initiator is 500-50000.
4. The preparation method according to claim 3, characterized in that: The molar ratio of the monomer of formula (II) to the monomer of formula (III) is (2-8):(15-40); The molar ratio of the initiator, the monomer of the structure of formula (II) and the monomer of the structure of formula (III) is 1:(2-8):(15-40).
5. The preparation method according to claim 2, characterized in that: The polymerization reaction is carried out under the protection of an inert gas; the inert gas includes nitrogen; the polymerization reaction temperature is 20-30° C. and the time is 2-3 days.
6. The preparation method according to claim 2, characterized in that: The reaction further includes sedimentation and drying to obtain a reactant; the reactant is dissolved in a solvent, trimethylsilyl bromide and triethylamine are added for reflux reaction, the solvent is removed, the pH value is adjusted after the solid is dissolved, and freeze-dried to obtain the product.
7. The preparation method according to claim 6, characterized in that: The precipitation is precipitation in ice ether; the drying is vacuum drying; the solvent is chloroform; the temperature of the reflux reaction is 55-65° C., and the time is 7-10 hours.
8. Use of the polymer according to claim 1 or the polymer prepared by the preparation method according to any one of claims 2 to 7 in the preparation of drugs for treating tumors.
9. An assembly, characterized in that: The polymer is obtained by reacting the polymer described in claim 1 or the polymer prepared by the preparation method according to any one of claims 2 to 7 with alkaline phosphatase and then self-assembling.
